These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Expression of human alpha1-antitrypsin in mice and dogs following AAV6 vector-mediated gene transfer to the lungs. Halbert CL; Madtes DK; Vaughan AE; Wang Z; Storb R; Tapscott SJ; Miller AD Mol Ther; 2010 Jun; 18(6):1165-72. PubMed ID: 20372105 [TBL] [Abstract][Full Text] [Related]
5. Efficient hepatic delivery and expression from a recombinant adeno-associated virus 8 pseudotyped alpha1-antitrypsin vector. Conlon TJ; Cossette T; Erger K; Choi YK; Clarke T; Scott-Jorgensen M; Song S; Campbell-Thompson M; Crawford J; Flotte TR Mol Ther; 2005 Nov; 12(5):867-75. PubMed ID: 16085464 [TBL] [Abstract][Full Text] [Related]
6. Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Lu Y; Song S Proc Natl Acad Sci U S A; 2009 Oct; 106(40):17158-62. PubMed ID: 19805176 [TBL] [Abstract][Full Text] [Related]
7. Efficient transduction of vascular endothelial cells with recombinant adeno-associated virus serotype 1 and 5 vectors. Chen S; Kapturczak M; Loiler SA; Zolotukhin S; Glushakova OY; Madsen KM; Samulski RJ; Hauswirth WW; Campbell-Thompson M; Berns KI; Flotte TR; Atkinson MA; Tisher CC; Agarwal A Hum Gene Ther; 2005 Feb; 16(2):235-47. PubMed ID: 15761263 [TBL] [Abstract][Full Text] [Related]
8. Generation of efficient human blood progenitor-targeted recombinant adeno-associated viral vectors (AAV) by applying an AAV random peptide library on primary human hematopoietic progenitor cells. Sellner L; Stiefelhagen M; Kleinschmidt JA; Laufs S; Wenz F; Fruehauf S; Zeller WJ; Veldwijk MR Exp Hematol; 2008 Aug; 36(8):957-64. PubMed ID: 18495326 [TBL] [Abstract][Full Text] [Related]
9. Preclinical evaluation of a recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin made using a recombinant herpes simplex virus production method. Chulay JD; Ye GJ; Thomas DL; Knop DR; Benson JM; Hutt JA; Wang G; Humphries M; Flotte TR Hum Gene Ther; 2011 Feb; 22(2):155-65. PubMed ID: 20812844 [TBL] [Abstract][Full Text] [Related]
10. Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors. Song S; Embury J; Laipis PJ; Berns KI; Crawford JM; Flotte TR Gene Ther; 2001 Sep; 8(17):1299-306. PubMed ID: 11571566 [TBL] [Abstract][Full Text] [Related]
11. Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Brantly ML; Spencer LT; Humphries M; Conlon TJ; Spencer CT; Poirier A; Garlington W; Baker D; Song S; Berns KI; Muzyczka N; Snyder RO; Byrne BJ; Flotte TR Hum Gene Ther; 2006 Dec; 17(12):1177-86. PubMed ID: 17115945 [TBL] [Abstract][Full Text] [Related]
12. Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Song S; Goudy K; Campbell-Thompson M; Wasserfall C; Scott-Jorgensen M; Wang J; Tang Q; Crawford JM; Ellis TM; Atkinson MA; Flotte TR Gene Ther; 2004 Jan; 11(2):181-6. PubMed ID: 14712302 [TBL] [Abstract][Full Text] [Related]
14. Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults. Flotte TR; Brantly ML; Spencer LT; Byrne BJ; Spencer CT; Baker DJ; Humphries M Hum Gene Ther; 2004 Jan; 15(1):93-128. PubMed ID: 14965381 [TBL] [Abstract][Full Text] [Related]
15. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Brantly ML; Chulay JD; Wang L; Mueller C; Humphries M; Spencer LT; Rouhani F; Conlon TJ; Calcedo R; Betts MR; Spencer C; Byrne BJ; Wilson JM; Flotte TR Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16363-8. PubMed ID: 19706466 [TBL] [Abstract][Full Text] [Related]
16. Intrapleural administration of a serotype 5 adeno-associated virus coding for alpha1-antitrypsin mediates persistent, high lung and serum levels of alpha1-antitrypsin. De B; Heguy A; Leopold PL; Wasif N; Korst RJ; Hackett NR; Crystal RG Mol Ther; 2004 Dec; 10(6):1003-10. PubMed ID: 15564132 [TBL] [Abstract][Full Text] [Related]
17. Improvement of Photoreceptor Targeting via Intravitreal Delivery in Mouse and Human Retina Using Combinatory rAAV2 Capsid Mutant Vectors. Reid CA; Ertel KJ; Lipinski DM Invest Ophthalmol Vis Sci; 2017 Dec; 58(14):6429-6439. PubMed ID: 29260200 [TBL] [Abstract][Full Text] [Related]
18. Ex vivo transduction and transplantation of bone marrow cells for liver gene delivery of alpha1-antitrypsin. Li H; Lu Y; Witek RP; Chang LJ; Campbell-Thompson M; Jorgensen M; Petersen B; Song S Mol Ther; 2010 Aug; 18(8):1553-8. PubMed ID: 20551917 [TBL] [Abstract][Full Text] [Related]
19. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Burger C; Gorbatyuk OS; Velardo MJ; Peden CS; Williams P; Zolotukhin S; Reier PJ; Mandel RJ; Muzyczka N Mol Ther; 2004 Aug; 10(2):302-17. PubMed ID: 15294177 [TBL] [Abstract][Full Text] [Related]
20. An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes. Kang W; Wang L; Harrell H; Liu J; Thomas DL; Mayfield TL; Scotti MM; Ye GJ; Veres G; Knop DR Gene Ther; 2009 Feb; 16(2):229-39. PubMed ID: 18923452 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]